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Objective: The objective of this registry is to establish safety and efficacy of BioMatrix,
BioMatrix-Biolimus A9 eluting stent in diabetic population in India.
Background: Diabetes mellitus is a major predisposing factor for coronary artery disease.
Prognosis for diabetic population patients presenting with coronary artery disease who
undergo coronary revascularization is inferior to non diabetics and remains an indepen-
dent risk factor of restenosis, need for revascularization, and overall mortality. Stent
thrombosis is a potential complication of first generation, permanent polymer drug-eluting
stents. Biodegradable polymer is a good relief in this era and its utility in diabetic patients
will be a major advantage for them.
Methods: 334 patients with diabetes mellitus and requiring angioplasty, implanted with
BioMatrix stent were followed at 1, 6, 12 and 24 months who entered in a multicenter
registry in India. We analyzed the incidence of major adverse cardiac events (MACE) and
stent thrombosis (ST) at 1, 6, 12 and 24 months.
Results: The mean age was 58.71  9.2 years, 81% were males, comorbidity index was
1.6  1.02, and 59.1% presented with acute coronary syndrome. The incidence of adverse
event rates was: MACE 1.27%. There were no incidences of myocardial infarction (MI) and
target vessel revascularization (TVR). Definite stent thrombosis occurred only in 2 patients.partment, India. Tel.: þ91 (0) 7387777465.
ndia.com (H. Rangnekar).
2013, Cardiological Society of India. All rights reserved.
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 5 8 6e5 9 2 587Conclusion: In this registry of diabetic population treated with BioMatrixTM-Biolimus A9TM
eluting stent (BioMatrix), the reported incidence of MACE and ST were much lower than
previously published results. The 1- and 2-year follow-up result supports favorable clinical
outcomes of using BioMatrix stents as a suitable alternative to contemporary DES available
during PCI in diabetic patients.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction growth, and proliferation. The safety and efficacy of BioMatrixDiabetics are prone to coronary artery disease (CAD) along
with other conditions. Patients with CAD and diabetes melli-
tus (DM) undergoing percutaneous coronary intervention (PCI)
are at significantly increased risk for short and long term
adverse clinical outcomes.1,2 The underlying mechanism is
due to the more diffuse and accelerated form of atheroscle-
rosis and endothelial dysfunction which lead to diffused cor-
onary lesions, small vessel disease, multi-vessel involvement,
larger plaque burden as well as higher incidence of left main
and ostial lesions.3 Diabetic patients respond less favorably to
revascularization and have higher restenosis rates. Never-
theless, stent thrombosis (ST) still remains the main safety
concern and long term complication associated with the use
of both bare metal stents (BMS) and drug eluting stents (DES).
The use of effective DES has definitely reduced the restenosis
rates and the need for repeat intervention as compared with
BMS, which has brought great hope of providing diabetic pa-
tients better and longer-lasting interventional solutions.4e8
Thus, DES has greatly improved clinical outcomes in dia-
betic patients. Still, smaller vessels (decreased lumen) in dia-
betic patients remain an important predictor of restenosis
even in the era of DES.9,10 There may be an increased athe-
rothrombotic risk in DM patients due to hyperglycemia, and
an improved glycemic control has been shown to improve
blood thrombogenicity.11
Current polymer-based, DES allow for controlled release of
therapeutic agents at the site of injury. Most effective drugs
utilized with DES for prevention of restenosis up to this point
in time have been sirolimus12e16 and paclitaxel.17e19 Large
cohort studies8,20 have reported rates of ST between 0.7% and
1.7% in the first year and <0.6% in subsequent years depend-
ing on the type of DES implanted, and the population studied.
BioMatrix-Biolimus A9 eluting stent (BA9) (BioMatrix)
is a new generation DES incorporating a biodegradable poly-
mer containing the anti-proliferative drug Biolimus A9 that
is only coated on the abluminal side. The proprietary is a
semi-synthetic sirolimus analog and shares a similar adverse
event profile when used at equivalent dose levels. It is highly
lipophilic, (10 timesmore than its analogs) rapidly absorbed in
tissues, and able to reversibly inhibit growth factor-
stimulated cell proliferation. With the facts, very highly lipo-
philic BA9 andwhich is coated only on the abluminal surface
of the stent assures targeted action of the drug. Moreover,
systemic exposure of the drug and the polymer is avoided by
this technology. Current data shows that BA9 on amolecular
level forms a complex with the cytoplasmic proteins that
inhibit the cell cycle between the G0 and G1 phase. The result
is an interruption of the cascade governing cell metabolism,stents has been established in several large randomized
controlled trials including LEADERS trial,21 which showed
BA9TM with biodegradable polymer had 80% relative risk
reduction of very late stent thrombosis (1e4 years) when
compared to first generation durable polymer DES.
This registry was initiated with aim to gather the clinical
outcomes of diabetic patients receiving the BioMatrix stents.
We captured 1- and 2-year incidence rates of MACE and ST
from this multicenter post market surveillance registry.2. Methodology
This is a prospective observational study of diabetic patients
who underwent implantation of BA9 eluting stent, ‘Bio-
Matrix’ conducted at seven interventional cardiology sites in
India betweenApril 2009 andDecember 2011. This prospective
study was conducted with prior notification to DCGI and with
EC approval of individual centers. Study was registered with
clinical trial registry of India with CTRI number: CTRI/2011/10/
002088. Primary endpoint of this registry was major adverse
cardiac events (MACE) defined as composite of cardiac death,
myocardial infarction (MI), or target vessel revascularization
(TVR) within the study population at 12 months of follow-up.
Secondary outcomes were stent thrombosis (ST) at 1, 6 and 12
months and 2 years; Patient oriented composite endpoint
defined as any cause mortality, MI, or any clinically driven
TVR at 1, 6 and 12 months and 2 years, and total revasculari-
zation rate at these time points. However, in this interim
analysis, primary endpoint is looked at along with ST.
The inclusion criteria for the study were diabetic patients
(Type I or Type II diabetes with documented treatment with
insulin or oral hypoglycemics or undocumented or newly
diagnosed diabetics with either blood sugar fasting value
>115 mg/dl, post meal 140 mg/dl or glycosylated hemoglobin
>7.3%), eligible for PCI with lesions suitable for stent im-
plantation with age 18 years, presence of 1 coronary artery
stenoses in a native coronary artery, saphenous bypass graft
or radial vein graft from 2.25e4.0 mm in diameter that can be
covered with one or multiple stents. Patients excluded were:
patients needing additional stent not of the BA9 eluting stent
type; receiving in addition to the Biolimus eluting stent and/or
other coronary vascular interventions like balloon angio-
plasty; receiving the BioMatrix stent during index and/or
staged procedure and if admitted for treatment of diabetic
ketoacidosis 2 times in the past 6 months. EC approved
consents for participation were obtained from each willing
and eligible patient before or after PCI who underwent
Table 1 e Age group distribution.
Age group %
30e40 0.6%
40e50 14.5%
50e60 37.4%
60e70 33.8%
70e80 12.5%
80 1.2%
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procedures.
The baseline data were collected from enrolled patients.
Implantation of BioMatrix-Biolimus A9 eluting stent, Bio-
Matrix in each target lesion during the index procedure was
mandatory. The appropriate length and diameter of the stents
to be implanted ensuring complete coverage of the lesion
were chosen by visual estimate. The stent length ranged be-
tween 8 and 28 mm (20.88  5.9), with long length lesion in
30.99% patients, and the nominal stent diameter ranged be-
tween 2.2 and 4.0 mm (2.88  0.4), with 2.75 mm in 50.74%
patients. Multiple stents were implanted in 66 (19.76%) pa-
tients. At least 2 mm overlap was achieved if more than one
stent was implanted. Treatment of multiple target vessels
(within the same procedure) and staged procedures which
occur within 90 days of the initial implant procedure were
allowed. All postoperative medical management, including
dual antiplatelet therapy, was prescribed according to usual
local practice at the discretion of the cardiologist. Data
collected by the registry include demographic information,
cardiovascular history, comorbidity, lesion and procedure
characteristics, and antiplatelet regimens. Patients were fol-
lowed at 30 days, 6, 12, 24 months by on-site visit with the
study physicians or by telephone communication. Interven-
tional cardiologists selected to participate as investigators in
this registry were qualified and/or board certified. All the pa-
tients were followed for up to 2 years after stent implantation.
The study data were verified on-site by the study monitoring
group for consistency with source data and to ensure
compliancewith the protocol aswell aswith Indian regulatory
guidelines.
The drug-eluting coronary stent system (BioMatrix DES)
is comprised of two key components: the stent (which in-
cludes Biolimus A9 incorporated into a polymer coating),
and the delivery catheter. A balloon expandable 316L stainless
steel stent with polymer coating containing Biolimus A9 is
pre-mounted onto a high pressure, semi-compliant rapid ex-
change balloon delivery system available in six and nine cell
models. The delivery catheter has two radiopaque markers,
which fluoroscopically mark the ends of the stent to facilitate
proper stent placement. The nominal dosage of Biolimus A9
for the BioMatrix stent ranges from 133 to 451 mg depending
on stent length. The biodegradable polymer is polylactic acid
(PLA), which has been widely used in a variety of medical
applications, including orthopedic and dental devices and
implants. BioMatrix is Biosensors’ DES having abluminal
coated biodegradable polymer. Its abluminal coating (coating
only to outer surface) is absorbed after 6e9 months and turns
the DES into a BMS. It combines the proven safety of a DES
with an abluminal biodegradable polymer, the proven efficacy
of BA9 and an advanced stent design. As this DES virtually
becomes a BMS after 6e9 months, long term safety to the
patients is ensured. As there is no polymer present, no drug
present after 6e9 months, incidence of ST falls considerably.
An independent clinical events committee adjudicated all
MACEs and other serious adverse events developing in the pa-
tient population. The committee arbitrated all MACE, other SAE
and ST by a systematic review of the data collection forms and
by review of the source documents, electrocardiograms, and
angiograms in case of suspected stent thrombosis and MACE.As this is an interim analysis and follow-up is in progress,
we have different quantum of follow-up done for patients.
Calculations in the paper are based on person-year calcula-
tions. Definition of Person-Year: A measurement combining
the number of persons and their time contribution in a study.
All statistical analyses were performed with SPSS (Version
16.0). Standard descriptive statistics were used for baseline,
lesion, and procedural characteristics and for clinical results
for all patients. Continuous variables were presented as
mean  SD and range, and categorical variables were pre-
sented as numbers and percentages. Descriptive data of the
patient population and serious adverse events were compiled
as per protocol specified time intervals.3. Results
336 patients were enrolled but 334 were followed up. The data
of these 334 patients were collected between April 2009 and
December 2011 and the results are mentioned below. The
interim analysis includes data of 393.2 person-year follow-up.
As this is an interim analysis and follow-up is still on, person-
year calculation is considered. The mean age was 58.71  9.2
years (range 36e83), comorbidity index was 1.6  1.02, angio-
graphic LVEF(%) was 52.09  11.36% (range 20e81) of which 60
(20.0%) had angiographic LVEF 40%. The patients included
were compliant with the eligibility criteria specified in the
protocol. Subject age group distribution is described in Table 1.
Patients’ baseline characteristics were as per listed in
Table 2. Around, 19% (65) patients were insulin dependent
(IDDM), and 81% (271) patients were non-insulin dependent.
Two third of the patients (65.3%) had hypertension, 22.8% had
family history of CAD, 16.6% had hypercholesterolemia and
22.3% had suffered previously with MI, 59.1% presented with
acute coronary syndrome. A total of 471 BioMatrix DES (1.41
stents/patient) were implanted during the index procedure, to
treat a total of 454 lesionswith aminimumof 1 andmaximum
of 6 lesions in 334 patients. The total lesion segment per-
centage is described in Table 3. Table 4 shows the number of
patients who were taking dual antiplatelet therapy (DAPT) at
1,6 and 12 months.
Non-hierarchy approach was used for counting of MACE.
The cumulative rate of MACE is presented in Table 5 and
overall stent thrombosis classification (as per ARC definitions)
is presented in Table 6. The incidence rate per 100 person-year
was 1.27 for all MACE. There were 3 cases of Re-PCI, but all
happened in non-targeted vessel. Two year follow-up of 111
patients (33%) was completed till this interim report. There
Table 2 e Baseline characteristics.
Baseline
characteristics
% Baseline
characteristics
%
Diabetes mellitus 100 Male 81%
IDDM 19 Female 19%
Current smoker 9.8 Average age (yrs.) 58.71
Renal insufficiency at
screening
0.9 Average LVEF 52.09
Hypertension 65.3 Total number of lesions
treated
454
Hypercholesterolemia 16.6
LVEF<40% 20.13
Family history of CAD 22.8 Lesion per patient 1.36
Stroke 1.2 Total number of stents 471
Congestive heart
failure
1.5 Stent per patient 1.41
Previous myocardial
infarction
22.3 Long length (>28 mm) 30.99
Previous CABG 5.6 Small vessel (2.75 mm) 50.74
Previous PCI(s) 8.3 Lesion treated previously 1.27
Acute coronary
syndromes
59.1 Total occlusion 8.38%
Asymptomatic 15.0 Device success 100%
Silent ischemia only 4.2 Single vessel (SVD) 74.9%
Stable angina 21.7 Multi-vessel (MVD) 25.1%
Table 4 e Patient taking DAPT.
DAPT Visit description
30 days
follow-up
6 months
follow-up
12 months
follow-up
Patient taking
DAPT
99.4% 99.7% 98.8%
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the 2-year follow-up of these 111 patients. The overall inci-
dence of ST, including probable and possible ST was 0.8 per
100 person-year. Definite stent thrombosis occurred in 2 pa-
tients only.Table 5 e Major adverse cardiac events.
MACE (major adverse Numbers Total Incidence rate4. Discussion
The interim analysis findings from our e-BioMatrix registry
show that BioMatrix-Biolimus A9 eluting stent with
biodegradable polymer can improve clinical outcomes in
diabetic population for up to 2 years. Thus, it contributes
significantly towards determining incidence and relative
clinical impact of MACE and ST in a large post-marketing
surveillance registry, which is one of the largest studies
dedicated to diabetic population in India. Diabetic patients are
known to be at high-risk for developing cardiovascular dis-
ease, increased restenosis, accelerated atherosclerosis and
more diffuse diseases. There is always a debate in themedical
fraternity regarding use of DES in DM patients.2
So far, two randomized trials exclusively with diabetic
patients have been published, that we know, with an angio-
graphic primary endpoint at 9 months. The first diabetes trialTable 3 e Total percentage of lesion segments.
Lesion segment %
RCA 27.04
LAD 42.79
LCX 27.27
Left main 0.66
Venous graft bypass 1.77compared SES and BMS in 80 diabetic patients with SES
showing TLR of 7.3% and MACE of 11.3% at 9 months.22 The
second is the ISAR-Diabetes registry23 study showing
intermediate-term follow-up on diabetes patients, the TVR
after SES implantation was 6.4% and there were no clinical
differences between SES and PES in the clinical endpoints at
the end of follow-up.
A lot of clinical studies included only subgroups of diabetic
mellitus patients and were not solely dedicated to these pa-
tients.24 Usually data accumulated over the years are derived
from subgroup, post-hoc analysis of diabetics included in
various clinical trials or from single andmulticenter registries.
Randomized controlled trials do not represent the complex
diabetic population seen in daily practice due to vessel and
patient selection criteria. Moreover, meta-analysis, with more
statistical power, does not allow for a systematic evaluation of
important biological confounders (diabetes control, lipid
concentrations, blood pressure, or inflammatory markers)
that may affect outcomes.
The subgroup studies include the SIRIUS trial25 with 131
diabetic patients with SES, and the TAXUS IV trial5 with 155
diabetic patients with PES. The clinical benefits of DES as
compared to BMS at 12 months were lower rates of TLR (6.9%
and 7.4%), TVR (9.9% and 11.3%), target vessel failure (TVF)
(12.2% and 15%), and MACE (9.2% and 15.6%) respectively. In
single center prospective Cypher (RESEARCH) and Taxus (T-
Search) registries involving 293 diabetic patients (SES, 145 and
PES, 148), mortality was similar in ITDM (11.6%) and in NITDM
(6.2%), and the MACE rate was only significantly higher in
ITDM by univariate analysis (27.4% vs. 14.6%). Clinical end-
points of different DES were shown to be comparable among
SES, PES and ZES in the SCARR26 registry in the subgroup of
diabetic patients. Furthermore, consistently lower rates of STcardiac event) MACE per 100 person-
year
Cardiac death 5 5 1.27
Myocardial infarction 0
TVR 0
* Major adverse cardiac events (MACE) within the study population,
defined as composite of cardiac death, myocardial infarction (Q-
wave and non Q-wave), or justified target vessel revascularization
at 12 months.
Non-hierarchy approach was used for counting of MACE.
Table 6 e Stent thrombosis.
Stent thrombosis Acute Subacute Late Very late Total Incidence rate per 100 person-year
Definite 1 1 0 0 2 0.8
Probable 0 1 0 0 1
Total 3
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stents in diabetics, particularly over long follow-ups. In the
BerneRotterdam registry, the rate of definite ST was 3.6% at 4
years with paclitaxel-eluting stents vs. 2.7% with SES.27 To
date, the BARI trial25 has been used as a reference for treat-
ment of the diabetic population with cardiovascular disease,
which suggested that CABG patients had improved survival
compared to angioplasty. At one year, CARDia trial28 showed
no apparent difference between these two treatment options
in terms of death or composite of death, non-fatal myocardial
infarction and non-fatal stroke which suggested that PCI is a
safe alternative to CABG in selected patientswith diabetes and
multi-vessel coronary artery disease. In this regard, our reg-
istry shows a lower definite and probable ST of 0.8 in 393
person-year followup, which is an indication of benefit of BA9
eluting stent in high-risk diabetic population.
Supporting this, the LEADERS trial29 has demonstrated re-
sults favoring to BES over SES where 26% were patients with
diabetes mellitus. There was 80% relative risk reduction in ST
as compared to permanent polymer DES, in the long run (post
one year, at least up to four years). Couple of other random-
ized trials have also supported the established results.30,31
More complete strut coverage was observed in an optical
coherence tomography substudy32 of the LEADERS trial pa-
tients allocated to BESs at 9monthswhen comparedwith SESs
suggesting complete endothelialization, which may have
impact on clinical outcome and, in particular, on the risk of
late stent thrombosis. The potential clinical advantage of BES
is expected to fully emerge during longer-term follow-up once
the polymer is completely metabolized.
Most of the earlier trials have reported significantly higher
rates of MACE as compared to our study results. In German
Cypher Stent Registry,33 reported MACE rate in the DM group
was significantly higher than in the non-DM group (16.4% vs.
13.0%) at 6 months but lower than expected from historical
data with the use of BMS, which was really encouraging.
MACE rate in both group (IDDM and NIDDM) were comparable
(16.3% vs. 16.4%) at 1-year in the SPIRIT V Diabetic Study,34
which was a randomized trial in a high-risk group of dia-
betic patients, implantation of EES compared with PES. These
reported rates are much higher than the results we observe in
this diabetic registry thus so far.
A recently published pooled analyses35 of various DES or
BMS in diabetic patients from 42 randomized trials demon-
strated that new generation stents are efficacious and safe.
Long term results are unknown, making speculative any as-
sumptions on the potential benefit of DES on mortality and
rate of MI in diabetic patients.
We have reported 1-and 2-year follow-up data from our
registry of diabetic patients who received BioMatrix stents.
The incidence of MACE (cardiac death, MI, TVR) and stentthrombosis (definite and probable) were significantly lower
(1.27 and 0.8, respectively) than previously published data
from trials following diabetic cohort. It also reveals a good
overall reported compliance with the administration of an-
tiplatelet therapy after PCI. Thus, in patients with diabetes
mellitus, 1 and 2-year outcomes (of 111 patients) from the
present interim analysis show substantial benefit after
treatment with BioMatrix stents as compared to other de-
vices. BA9 eluting stents appears to have comparable and
favorable clinical outcome in the high-risk diabetic
population.5. Study limitations
Since patients treated with other than Biolimus stents during
the index procedure was an exclusion criterion, no infor-
mation was collected on other DES, which might have
contributed to some degree of selection bias. However, this
was the very intention of the study, to know safety and
efficacy of BioMatrix-Biolimus A9 eluting stent in diabetic
patients in India. Secondly, the study design was single-arm
with no control arm for direct comparison. However, these
limitations are part of any post-marketing surveillance
registry.6. Conclusion
In conclusion, the 1-and 2-year incidence of MACE in this
diabetic population treated with BioMatrix stents is signifi-
cantly lower as compared to previously published data. The
incidence of ST is lower than similar recent registries. These
results could be due to unique combination of Biolimus A9
drug (which is 10 times more lipophilic than its analogs),
biodegradable polymer PLA and technology of abluminal
coating. These support favorable clinical outcomes of using
BioMatrix stents as a suitable alternative to contemporary
DES during PCI in diabetic patients. Highlights like advanced
stent design, highly lipophilic Biolimus A9 drug, biodegrad-
able polymer (PLA) and their application on the abluminal
side of the stent could be responsible for such encouraging
results of BioMatrix BES. This registry is especially important
for Indian set-up, where increasing prevalence of diabetes is
a concern.Conflicts of interest
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